<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Rodin D</submitter><funding>NCI NIH HHS</funding><pagination>915-923</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7055962</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>20(7)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Radiotherapy is standard of care for cervical cancer, but major global gaps in access exist, particularly in low-income and middle-income countries. We modelled the health and economic benefits of a 20-year radiotherapy scale-up to estimate the long-term demand for treatment in the context of human papillomavirus (HPV) vaccination.&lt;h4>Methods&lt;/h4>We applied the Global Task Force on Radiotherapy for Cancer Control investment framework to model the health and economic benefits of scaling up external-beam radiotherapy and brachytherapy for cervical cancer in upper-middle-income, lower-middle-income, and low-income countries between 2015 and 2035. We estimated the unique costs of external-beam radiotherapy and brachytherapy and included a specific valuation of women's caregi</pubmed_abstract><journal>The Lancet. Oncology</journal><pubmed_title>Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact.</pubmed_title><pmcid>PMC7055962</pmcid><funding_grant_id>K08 CA230170</funding_grant_id><funding_grant_id>U54 CA190158</funding_grant_id><pubmed_authors>Grover S</pubmed_authors><pubmed_authors>Zubizarreta E</pubmed_authors><pubmed_authors>Barton M</pubmed_authors><pubmed_authors>Hanna TP</pubmed_authors><pubmed_authors>Lievens Y</pubmed_authors><pubmed_authors>Jaffray DA</pubmed_authors><pubmed_authors>Atun R</pubmed_authors><pubmed_authors>Rodin D</pubmed_authors><pubmed_authors>Gospodarowicz M</pubmed_authors><pubmed_authors>Burger EA</pubmed_authors><pubmed_authors>Knaul FM</pubmed_authors><pubmed_authors>Milosevic M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact.</name><description>&lt;h4>Background&lt;/h4>Radiotherapy is standard of care for cervical cancer, but major global gaps in access exist, particularly in low-income and middle-income countries. We modelled the health and economic benefits of a 20-year radiotherapy scale-up to estimate the long-term demand for treatment in the context of human papillomavirus (HPV) vaccination.&lt;h4>Methods&lt;/h4>We applied the Global Task Force on Radiotherapy for Cancer Control investment framework to model the health and economic benefits of scaling up external-beam radiotherapy and brachytherapy for cervical cancer in upper-middle-income, lower-middle-income, and low-income countries between 2015 and 2035. We estimated the unique costs of external-beam radiotherapy and brachytherapy and included a specific valuation of women's caregi</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Jul</publication><modification>2025-04-22T00:21:37.329Z</modification><creation>2020-10-29T15:41:40Z</creation></dates><accession>S-EPMC7055962</accession><cross_references><pubmed>31151906</pubmed><doi>10.1016/S1470-2045(19)30308-0</doi><doi>10.1016/s1470-2045(19)30308-0</doi></cross_references></HashMap>